GSK525762 Medicine 12 June 2019 Extended indication NUT midline carcinoma (NMC) (een vorm van "squamous cell epithelial cancer") Therapeutic value No judgement Total cost Registration phase Clinical trials Product Active substance GSK525762 Domain Oncology and Hematology Reason of inclusion New medicine (specialité) Main indication Oncology other Extended indication NUT midline carcinoma (NMC) (een vorm van "squamous cell epithelial cancer") Current proprietary name Already available biosimilars / generics Proprietary name Manufacturer GSK Portfolio holder Mechanism of action BET inhibitor Route of administration Oral Therapeutical formulation Unknown Budgetting framework Intermural (MSZ) Centre of expertise Additional remarks BET family bromodomain inhibitor Registration Registration route Centralised (EMA) Type of trajectory Unknown Particularity Unknown ATMP Unknown Submission date 2020 Expected Registration 2021 Orphan drug Unknown Registration phase Clinical trials Reimbursement Medicine sluice Additional remarks Therapeutic value Current treatment options Therapeutic value No judgement This assessment does not indicate any potential inclusion in the package. Substantiation Duration of treatment Frequency of administration Dosage per administration References NCT01587703 Additional remarks gezien de vroege fase van klinische studies is het nog onduidelijk welke therapeutische waarde het middel mogelijk heeft en wat het behandelschema zal worden. Expected patient volume per year Patient volume Market share is generally not included unless otherwise stated. Maximum patient volume for sluice References Additional remarks Betreft een ultra-zeldzame vorm van kanker, zeer klein aantal patiënten verwacht die hiervoor in aanmerking gaan komen. Expected cost per patient per year Cost References Additional remarks Potential total cost per year Total cost Total cost for sluice Additional remarks Off label use Off label use Unknown Indications off label use References Additional remarks Indication extension Indication extensions Yes Indication extensions Lopende studies o.a. naar het effect bij Solide tumoren References clinicaltrials.gov Additional remarks Other information Additional remarks